Date published 
July 2013

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Molecular Biomarkers for Cancer Detection and Management: Tables and Figures

TABLES

  • Exhibit 4.1 Screening, detection, risk, and monitoring biomarkers 
  • Exhibit 4.2 Prognosis and prediction biomarkers
  • Exhibit 4.3 Companion diagnostic biomarkers
  • Exhibit 5.1 Estimated cancer biomarker manufacturer revenues (2012) and projections (2017), by segment (US$ in billions)
  • Exhibit 5.2 Selected recent cancer detection, risk, and prognostic assay deals
  • Exhibit 5.3 Selected recent companion diagnostic assay deals
  • Exhibit 5.4 Survey: Area of respondents’ work
  • Exhibit 5.5 Survey: Nature of respondents’ organization
  • Exhibit 5.6 Survey: Respondents’ position within their organization
  • Exhibit 5.7 Survey: Respondent’s biomarker focus (Multiple answers permitted; n=107)
  • Exhibit 5.8 Survey: Respondents’ organization employs which of the following technologies for cancer biomarker detection of measurement (Multiple answers permitted; n=100)
  • Exhibit 5.9 Survey: Statements regarding circulating tumor cells and nucleic acids (Multiple answers permitted; n=100)
  • Exhibit 5.10 Survey: Participation in companion diagnostics (Multiple answers permitted; n=100)
  • Exhibit 5.11 Survey: On a scale of 1 to 5, please rate the following entities as likely sources for new cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)
  • Exhibit 5.12 Survey: On a scale of 1 to 5, please rate the following technologies as likely means for detecting or measuring cancer biomarkers during the next five years (1=Highly unlikely; 5=Highly likely)

FIGURES

  • Figure 4.1 Cynvenio's LiquidBiopsy Platform